A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastoma

Affiliations

Comment

Stuart A Grossman et al. Neuro Oncol. 2017.

. 2017 Aug 1;19(8):1019-1020.

doi: 10.1093/neuonc/nox046.

¹ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

No abstract available

Comment on

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, Hegi ME, Zhang P, Golfinopoulos V, Perry JR, Hyun Nam D, Erridge SC, Corn BW, Mirimanoff RO, Brown PD, Baumert BG, Mehta MP, van den Bent MJ, Reardon DA, Weller M, Stupp R. Blumenthal DT, et al. Neuro Oncol. 2017 Aug 1;19(8):1119-1126. doi: 10.1093/neuonc/nox025. Neuro Oncol. 2017. PMID: 28371907 Free PMC article.

1. Einhorn LH, Williams SD, Loehrer PJ et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989;7(3):387–391. - PubMed
1. Pavlovsky S, Schvartzman E, Lastiri F et al. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin’s disease. J Clin Oncol. 1997;15(7):2652–2658. - PubMed
1. Hakes TB, Chalas E, Hoskins WJ et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol. 1992;45(3):284–289. - PubMed
1. Shulman LN, Cirrincione CT, Berry DA et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012;30(33):4071–4076. - PMC - PubMed
1. Qu JL, Li X, Qu XJ et al. Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer. PLoS One. 2013;8(12):e83196. - PMC - PubMed